Clinical Trial Search

Primary: Number of RA Participants in the 2011-2012 Season Who Achieved Seroconversion at Day 21 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant…

Primary: Number of Participants Who Obtained Final Clinical Cure of Index Lesion — 9; 13 Participants

Primary: Number of Patients Achieving Pathologic Response — 49 percentage of pathologic responders

Primary: Time to Hemostasis — 2.2; 4.4 minutes — p=0.004

Primary: Area Under the Curve (AUC) for Single Dose of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population — 125.6; 147220.2 pg*h/mL

Primary: Probability of Overall Survival at One Year — 0.66 probability of overall survival at 1 yr.

Primary: Number of Immunogenic Responders, With Response Defined as a 4-fold or Greater Increase in Serum Bactericidal Antibody Titers From Study Entry to Week 28 After 2 Doses…

Primary: Cumulative CD54 Upregulation Ratio Between Each of the Cohorts. — 29.53; 30.94; 26.67 Ratio ofCD54 molecules on BDS65:FP cells — p=0.5019

Primary: Mean Change in CD4+ T Lymphocyte Count — -21.8; 113.7; 110.4 cell/mm^3 — p=<.001

Primary: The Number of Subjects Who Had Either an Increase or Decrease on Bone Mineral Density of the Lumbar Spine and Femoral Neck in Men Undergoing Androgen Deprivation Therapy…

Primary: Number of Participants That Experienced Adverse Events — 0; 0; 0; 0 participants

Primary: Nature and Degree of Toxicity — 2; 4; 20; 19 Participants

Primary: Determine the Maximum Tolerated Dose of CC-4047 — 0; 0; 66 percentage of participants with DLT

Primary: Severity of Withdrawal Symptoms Measured Using the Clinical Opiate Withdrawal Scale (COWS) at Baseline and the Peak COWS up to 23.5 Hours After the First Administration…

Primary: Complete and Overall Response Rate — 50.0; 33.3; 93.8; 96.7 percentage of patients